1
Dec
2022
Alzheimer’s Debate, Nimbus to Challenge BMS, & a Microbiome First
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Nov
2022
Cajal Comes Out of Stealth with $96M for Alzheimer’s, Parkinson’s Drug Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Nov
2022
Delivery of Genetic Medicines: Shehnaaz Suliman on The Long Run
Today’s guest on The Long Run is Shehnaaz Suliman. Shehnaaz is the CEO of Menlo Park, California-based ReCode Therapeutics. Recode is working on lipid nanoparticles to improve the delivery of genetic medicines. These little packages have made it possible to deliver billions of mRNA COVID vaccines in people’s arms, saving millions of lives. It’s been two decades of hard work.... Read More
27
Oct
2022
Vaxcyte Takes on Pfizer, Novartis Challenges AZ, & Time Gets $100M
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Oct
2022
Single-Cell Analysis for Precision Medicine: Tariq Kassum on The Long Run
Today’s guest on The Long Run is Tariq Kassum. Tariq is the CEO of Cambridge, Mass.-based Celsius Therapeutics. Celsius emerged on the scene in May 2018 with a $65 million Series A led by Third Rock Ventures. It was built on the conviction that single cell analysis will shed light on new targets for the treatment of cancer, autoimmunity and... Read More
26
Oct
2022
Variant Bio Strikes New Pharma Bargain, Shares Benefits of Human Genetic Research
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Oct
2022
Bezos Bets on Fred Hutch, Prime Medicine Bucks the Trend, and PacBio Throws Down
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Oct
2022
Matchpoint Gets $100M to Take Covalent Binders Into Autoimmune Disease
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Oct
2022
Protein Degraders For Outside the Cell: Aetna Wun Trombley on The Long Run
Today’s guest on The Long Run is Aetna Wun Trombley. Aetna is the CEO of South San Francisco-based Lycia Therapeutics. Many in biotech know about targeted protein degraders. Arvinas and Kymera Therapeutics are a couple of the well-known companies that make these drugs which work to inhibit intracellular proteins. This approach has drawn a lot of excitement because it can... Read More
11
Oct
2022
Neumora Snaps Up $112M to Advance Precision Neuroscience Work Through Clinic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Oct
2022
Nobel for Bertozzi, Red Tree Eyes West Coast, & Doubling Down on Singapore
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Oct
2022
The Kilimanjaro Climb to Fight Cancer Is Back
I’m taking another biotech team to the highest peak in Africa. Four years after the first team expedition, the Kilimanjaro Climb to Fight Cancer is back with a new crew of 28 biotech executives and investors. Together, we’re going to push ourselves physically, and raise more than $1 million for research at the Fred Hutch Cancer Center. The expedition is... Read More
6
Oct
2022
Red Tree Debuts With $272M, Zeroing In On West Coast Startups
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Sep
2022
Eisai and Biogen Bounce Back, Amylyx Approved, & Illumina’s Big Reveal
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Sep
2022
Going Upstream Against Inflammation: Samantha Truex on The Long Run
Today’s guest on The Long Run is Samantha Truex. Samantha is the CEO of Waltham, Mass.-based Upstream Bio. Upstream came out of stealth mode with a $200 million Series A financing in June. It’s a big investment in an antibody aimed at the TSLP receptor. It’s a cytokine – an inflammatory protein – that sits at the top of what... Read More
22
Sep
2022
GSK Lifts Up Spero, AlphaFold Inventors Honored, and a Microbiome Milestone
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Sep
2022
Third Harmonic Revives IPO Market, PDUFA Deadline Nears, & Pfizer Aims mRNA at Flu
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Sep
2022
Pretzel Gets $72.5M for Gene Editing & Small Molecules Against Mitochondrial Targets
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Sep
2022
Amylyx’s ALS Surprise, Regeneron’s Eye Franchise Win & Roche Buys Good
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Sep
2022
Designing Gene Circuits For Cell Therapies: Tim Lu on The Long Run
Today’s guest on The Long Run is Tim Lu. Tim is the co-founder and CEO of South San Francisco-based Senti Biosciences. Senti is working to develop gene circuits for cell therapies. This is about reprogramming cell therapies with precise genetic instructions on what to do in certain circumstances. The code essentially can tell the cell to kill tumor cells with... Read More